IMM-1-104 Monotherapy (Treatment Group A)

Phase 2

Immuneering Corp (IMRX)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jun '27

IMRXPhase 2$290M

IMM-1-104 Monotherapy (Treatment Group A) Phase 2 Est. Readout

IMM-1-104 Monotherapy (Treatment Group A)• Advanced Solid Tumor209

Jun 2027~Estimated

CT.gov

00%

Competitive Landscape

7 competitors in Advanced Solid Tumor

Drug Information

Target Indication

Advanced Solid Tumor

Clinical Trial

NCT05585320

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

IMRX

Immuneering Corp

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

AtebimetinibPhase 3

Pancreatic Cancer

mGnPPhase 3

Pancreatic Cancer

IMM-1-104 + pembrolizumab (Treatment Group E)Phase 2

Advanced Solid Tumor

IMM-1-104 + modified FOLFIRINOX (Treatment Group C)Phase 2

Advanced Solid Tumor

IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)Phase 2

Advanced Solid Tumor

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts